Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I like the compromise ACT offers as much as anyone, it just might turn out to be a moot point in the long run. As for calling people, my point was that it would be unnecessary due to the news media reporting the RPE ESC trial. Fingers crossed the liberal media reports not only the company name but also makes a comparison between the two trials (GERN vs. ACT) plus contributes the additional information that it has such a compromise! This (my hope) would be enough. As for those whom cater to a more conservative crowd, It's JMO that even if you do your part and educate them they will continue to point out the advances made elsewhere and attempt, in return and on your dime, to get you to see things their way.
FWIW, best of luck doing your part.
The naysayers do know. Those opposed to hESC have, and probably will continue, to tactfully omit from any media the claims ACT makes out of fear that it would make the research that more justifiable to others sitting on the fence. And I wouldn't be surprised if FOX made no comment at all when this company files its IND just to avoid bringing attention to the research. It will not matter though, every one else will be all over it, no need to make any phone calls.
CIRM in meeting with industry execs to work out details of providing loans. Links to a transcript and presentation in which Gregory Bonfiglio, managing partner of Proteus Venture Partners, provides his thoughts on what venture capitalists are looking for and climate of the industry in general are below.
Tanscript
http://www.cirm.ca.gov/transcripts/pdf/2008/01-16-08.pdf
Slide Presentation. some interesting data.
http://www.cirm.ca.gov/meetings/pdf/2008/011608_item_3a.pdf
There are quite a few stem cell blogs now, but for any one interested in what's going on at the CIRM, you know, the guys handing out the grants here in California, you might check out this blog once in a while. http://californiastemcellreport.blogspot.com/
Anyone still here? thought I would mention CYOE.OB it's still speculative however I thought you may be interested in what they are marketing. If anything, there are other board members that would appreciate a woman's input.
Thankyou
FWIW, an interview by Barbara Walters will be airing in a few weeks. Most of us on the other board are aware of this but I suspect few others are.
here's a link.
http://www.encyclopedia.com/doc/1G1-171748907.html
What you do with the information is entirely up to you. I'll be honest the company is strapped for cash but if you do some DD you might like where they are headed. I would consider this a long term play, while some are clearly speculating the interview will bring in buyers in the near term.
by the way that's ACTC.OB
Those of you aware of the political situation that currently hinders these companies, may want to consider that it is likely the new administration will change the current policy in support of this research. This of course is months away but the effect will be positive for all these companies. You may want to pay some attention to a basket of these stocks as we draw closer to the election. STEM and GERN are two others. As for ACTC they will be entering phase II in a couple of months for a heart therapy using adult stem cells which has proven quite successful so far.
Every cell in the blastomere contains the same set of chromosomes so removing one cell does not mentally or physically change the outcome. Excuse the brief explanation but might explain why they don't mention something at this level. Good question though.
You may want to google PGD to read more. But the basic idea it that one cell is removed to screen for traits that are the cause of serious/fatal illnesses. If one cell contains an undesirable trait in its DNA then all the cells do. If this was not the case then PGD would not be of any use.
OT sort of. This is not indented to pump another stock, which I have mentioned before, but to illustrate how effective the news media can be in generating the much needed interest in a company.
If you go to the Sci/Tech section on google news (for example) you will find articles on Human stem cells created without destroying embryos. It is a sensitive topic I do not want to debate, but if you are interested you will see just why many people follow this company I am referring to.
I'll leave it at that, except to say perhaps, if this cell collector thing has any merit why is it hidden from the mainstream media? JMO it never will garner this type of attention until the SoftPap becomes a hit.
here's a link for you lazy people
http://www.timesonline.co.uk/tol/news/uk/science/article3168158.ece
OK small pump sorry, company is heading in to phase 2 trials: Therapy for heart failure and is getting grant money from NIH for research, something CYOE has never received.
"There is no spoon"................................
He has told you nothing new, only what you want to hear.
Everyone on this board and ragingbull, I imagine, has spoken to Gene in the past at some point and everyone by now is somewhat skeptical of anything he says. It is after all his job to sell the company stock.
When you have finished going through their financial statements let us know if it's still the bargain you believe it to be. Judging by some recent posts, people want to see money in the bank before they commit any more money to this.
good luck to you though.
Difficult to classify as a lie, yet with the company's combined experience and with at least one person having been involved in bringing new products to market I would expect they have a better understanding of how long the trials should take.
At some point someone is going to update the clinical trials web site and tack on another 3 months to the expected completion date. If they can't meet that then people are going to start losing interest in cytocore pretty quickly.
PR's continue to be very optimistic time wise just to keep investors hanging on but if you believe in this company then waiting a couple more years is not a big deal. I also expect the float will have been increased by almost 10%, I guess we'll know once they release the 10K.
At least there have been no more planned sales since November, maybe they are going to try and run it up again so the selling can begin all over again.
When I was at the meeting the product was sealed in small plastic baggies, and was told then that was the packaging (enough to protect the items from dust etc.) So I'm curious why they should have to ship product to Cytocore for QC and then repackage, it just does not vibe well with me. Shouldn't the manufacturers be responsible for QC and packaging too? If they really are going to check each one I admire the thoroughness but seems a little excessive, there's going to be a lot of collectors to inspect. Really thought product would go straight from manufacturer to distributor. Maybe just a one time thing. It all sounds plausible and yet it could be a stall tactic.
OK, now where did I put the salt.
What makes you think management has anything to lose? Last time management made a purchase was 9/25/05 at .10 cents. Most likely outcome is they will award themselves new options when it is most beneficial to them. With little money rolling in it will be the only way to maintain their interest in the company.
Pay close attention to any SEC filings in the next 6 months, I'm certain they will adjust their stock based compensation to make up for any loses the RS has done. May find it in the 10Q. A side note on the frequent changes in accounting firms, usually means that the old accounting firm refused to fudge the numbers on Cytocore's behalf, think about that!
Most brokers will provide detailed quotes on insider action but you can also find it here:
http://www.cnbc.com/id/15837285?q=cyoe
Funny thing is that one only gets to see who is dumping after the fact since the paper trial of whom they are selling equity interest to is next to nothing. Intentional in my opinion because they don't want retail to know how much they are diluting the float and at what price they are selling.
Flushhhhh. plunge protection team non existent here or maybe they went on vacation with your money. All I see is a 65% haircut in the past few days and possibly more to come.
Take deep breath, click sell and let someone else be the bag holder until the company shows it's worthy of your investment.
I see the roller coster is operating again.
Nice grab at $1.75. Don't let it go to your head though. I would consider selling them back at $2.00 for the rare opportunity of actually making some money back on this thing.
Almost forgot, GO CYOE!
Let's all post positive comments to see if that has an effect on the price.
I'll go next.
I'm backing up the truck here. cyoe is going to the moon!!!!
I'm all out! and it feels great knowing that what I have preserved can go into something else that I think will increase in value in the near to mid term.
And I'm not buying until sales volume increases and company has net positive earnings that are increasing qtr. over qtr. This could take years and I'm not sitting around hoping to find out.
If you don't think the trials are going to be completed by the end of the month it may be worth considering taking a loss for tax purposes before this thing falls any further. It's quite a drop after those bids at $2 are taken out. If there are any developments in the next 6 months that warrant taking a position chances are good that you can get back in near pre-split levels. Though my gut tells me that Martineau, et. all are busy selling equity in this company right now to raise capital which will only dampen moves to the upside. JMO of course.
Thanks for the link. Sure everyone knew the RS was inevitable, what gets me is the lack of shareholder notification on the selection of the ratio and the effective date.
I suppose the link provided by harr449 is meant to be a substitute for an SEC filing and/or press release.
It's going to be interesting to see what happens next.
PRVB, Thanks for the CPT info, thought I read every detail in that report.
Cycr would be donating the collector if they got involved with these charities. It might make a great right off though.
I'm gonna watch and wait all the same. If they stop robbing their shareholders and show positive, increasing net income for a couple of quarters then I may give them a vote of confidence, until then I can not speculate on what they release in their PR.
good nite
I agree if I sleep I'll lose my money in here. Must have been sleeping when they applied for it's CPT code, would you be so kind as to provide a link to that, others would like to know I'm sure. I might reconsider my position.
We have heard very little about the ongoing progress of the remaining product line, which has me thinking that nothing has been accomplished due to the effort of getting the collector out. For example, University Hospital CASE Medical Center is the only place recruiting with regards to the P2X7 study which suggests cycr does not have the money to spend on more clinical trial sites, not until they raise more money anyway. It could be just a lack of enrollment. I've looked for other ongoing trials and see nothing else beyond e2 and p2x7.
Also in their 3rd quarter financial results they list a bunch of accomplishments that consist mostly of head shuffling, they do that all the time anyway!
New contracts will appear at a logarithmic pace, replacing current distributors with new ones more like.
Many of us here work hard for our money, and should be no surprise that it be the focus of conversation. Love does not put a roof over my family's head these days. Ever ask why these guys never borrowed money from a bank for this 'great' idea of theirs. My guess, they could not raise the money that way so they find retail investors to pay for it.
Next year management will award themselves new stock options to replace the old ones, making the argument that the RS will affect everyone complete BS.
Is everyone paying homage to their PR's again? It wasn't long ago cycr was being ripped apart for not bringing this product out in mid 2007. Is the PR really under control? do you believe they have changed? Do you believe the float will not double again by next year?
Excuse me while I go back to sleep on this one.
I've asked IR for an update to the enrollment when they appeared to be late but I did not receive any information, since then of course they updated the expected end date to December. After that my research led me to believe that cycr is not to blame for the slow enrollment; getting women to return for a follow up exam and then signing up for the trial is. I have no doubt cycr will be the first to toot their horn as soon as they are done, or they will simply extend the completion date behind the scenes. I'm thinking 50/50 by the of March.
Having spain show interest in product development is a plus, cycr could use some help in getting things done. It's just that it could take another year before you hear of any progress in the AIPS and is not worth jumping on the bandwagon for, not right now anyway. You do realize the image on the cycr website is computer generated?! I mentioned before Monogen is already having their PMA reviewed for their automated slide system. This only puts more pressure on cycr to get things done ASAP. Whatever cycr does it always appears to be too little too late.
Yes PRVB they have agreements. The assumption going around is they may earn $1 per unit sold (sounds reasonable). With the current contracts that equates to 0.05 cents per share post split. A P/E of 100 makes that $5 post 1:10 RS. I'm not convinced the market will award this company such a high PE, not until they have shown the product is being adopted and selling well. Per usual we can only speculate on what they are actually earning on each item, it could be less. As I recall the handle alone costs almost $20 each to make and they may have to give these away at first to get doctors to try.
I am quite sure about one thing, they will continue to raise money to pay for their overhead by selling shares to other investors, diluting the float again. And it could be another year or two before you see positive earnings.
Why not wait until they have proven to be successful?
Sam, do the distributors like the potential? I can only guess. Based on the modest commitments to date I would say the distributors are only 'testing the water' at this stage. If for any reason these contracts are canceled then that's a sure sign these things are not selling well.
Do you think they will complete the trials by end of December?
It sounds like the distributors best guess of what they think they can sell for the opportunity to be the sole distributor in the region. If they don't sell Cytocore will say they are not trying hard enough and look for someone else. But in no way does this mean future income is set.
"Much of this reduction resulted from cashless settlements. The company expects to reduce liabilities to approximately $750,000 by year end."... by selling more of the company's equity at a discount to our friends and thus diluting the float further and we will continue to do so until our products make money.
Lumber Co. has planned sale of 823K shares. Maybe there will be another shameless pump before they announce the 1:10 RS to encourage retail to buy them.
Anyone keeping an eye on Monogen? Looks like they are getting primed to sell their automated slide processing system.
Experience with a new cervical smear sampling device.
The following is from an old report I found.
The cervical smear is effective in detecting the precursor lesions of cervical cancer. With appropriate treatment invasive carcinoma maybe prevented. A major cause of a non-diagnostic smear is poor sampling. A new sampling device, the Cervex-Brush, has been touted as being capable of producing a superior specimen compared with the modified Ayre's spatula, which is the most widely used cervical sampler in Hong Kong. When evaluated on 500 women, the Cervex-Brush was found to produce a good quality sample as judged by the presence of endocervical and/or metaplastic cells, lack of blood, and the thickness of the cell sample. In the drive to ensure that cervical smears are of the highest quality, the Cervex-Brush is worthy of further evaluation for routine use. Although it is significantly more expensive, the extra costs could be offset by the substantial savings that can accrue from having a smaller number of substandard samples and the need to repeat smears.
With the cost of medical care escalating at an alarming rate, two factors are of paramount importance in any health expenditure—cost effectiveness and cost containment. Therefore, should the Cervex-Brush, which is substantially more expensive, be used instead of the modified Ayre's spatula? Each Cervex-Brush costs approximately HK$1.80 to $2.50, depending on the supplier, while the wooden spatula costs from 5 to 25 cents, depending on the country of manufacture. Even with mass production techniques and bulk purchasing, the price of the Cervex-Brush is unlikely to approach the modest price of the wooden Ayre's spatula. However, there can be substantial savings if the number of inadequate smears that lack EECs or MCs can be reduced. Having to repeat a smear because of a previously inadequate sample not only requires a woman to be present for a further examination but also involves further nursing, medical, and staff laboratory time and effort. In addition, there are added stresses for the patient and more importantly, an inadequate sample may mean an undetected lesion and the development of a cancer in the future.
I just don't see a piece of plastic with a balloon on one end costing significantly more than a brush. Not significantly more to be considered anything outside of "usual and customary".
Spatulas and brushes are not free, someone is picking up the tab. If it is true that the labs give them away they are absorbing the cost/or passing on the expense somehow.
I'm not saying cost is not an issue. I thought the improvement in cell collection is an attempt to reduce the number of false positives (or is it negatives) that would lead a women to accrue unnecessary medical bills. Bills that the insurance company does not want to pay.
I agree, insurance companies would rather you die instantly than pay hospital fees.
Cost is always an issue, no matter where you are in the world, but to say India and China would not adopt something based on there current state of development is a little far fetched. They have had no problems in adopting many of our jobs and the income that comes with it. Let someone in India and China manufacture the product (sans lead paint) and the cost will be more in line with their expectations of what it should cost.
The current charge for a pap test to patients insurance is hell of a lot more than $15-$25 dollars. You're forgetting that the doctor likely charges $100+ for each visit, which is why many americans have insurance in the first place.
Correct me if I'm wrong, but It's my understanding that insurance companies don't concern themselves with the specific tools Doctors use in their practice of medicine. Therefore if any doctor sees fit in using the collector they will just bill the insurance company for reimbursement and the patient just pays the co-pay amount that the insurance company has agreed to for whatever the service was. If your insurance company specifically states that you can only have a pap test provided the samples were collected using a brush then you should change your insurance co.
An extra $10 (and I doubt it will come close to $10) is not going to phase an insurance company, certainly not if the device provides any evidence that it could save them money in the long run by paying for fewer surgeries/chemo etc. in the future. Will your insurance company balk at the cost, I think it unlikely in the grand scheme of things.
Everybody wins. No extra charge to patients, doctor reimbursed, insurance cuts expenses on other bills.
Anyone notice the contact info on the duplicate news release has changed?
looks like they have changed PR firms again.... bvk.com
Viruses do contain some DNA, hence the ability to genetically test. It has/is debated whether to consider them cells or not. The significant difference being that they can not duplicate themselves without attacking a host cell. Perhaps there is something specific about the cells they attack that allows them duplicate and spread.
It is my guess that HPV may not replicate with blood cells that leads me to think the test still requires a tissue sample. Also 'pap' or 'pap test' are referencing the technique with which the cells are currently identified, not inclusive of the collection.
Don't hold me to this 'till I find out for sure next week.
Exactly!
Not everything travels through your blood stream. Blood tests have their purposes for sure but when it comes to DNA a tissue sample rules.
I think if they could use blood they would already be using it.
Regardless of the type of test used, cells must to be collected from the area that is representative of where the virus is found, so no matter what other companies come up with in terms of detection the collector will always be needed for sample collection. From what I understand of Digene's HPV test it sounds like they are forgoing visual inspection and replacing it with a microarray similar to what is used in other genetic tests.
So we are back full circle. Confidence in HPV test a result of sample. How can you get a better sample!?
Maybe they haven't issued any more stock and would prefer to do so only after the RS. Considering that the time frame for when the RS can occur is open for months they may wait to see what happens after a significant announcement. I wouldn't say they have given up, they are attempting to attract OTHER investors. Maybe it's true, there is too much riffraff pushing pennies here to allow this to climb. A higher share price might actually smooth out the fluctuations.
When the company doesn't coddle the public with info, it's bad, when they do it's fake. The RS IMO is a great way to get rid of the fickle few.
I guess they feel the information is public already so there is no need to remind everyone.
Just to rephrase my point: the stigma of a RS is based on statistics that suggest its not good. However no one is looking at cycr as a unique case. As I said before there is no threat of being delisted, it's only fall from grace is that trials have not been completed according to some peoples schedule and apparently they have little debt to speak of. Fundamentally nothing has changed.
FWIW im holding my position, I don't like the idea that a PR could be posted after hours describing imminent success realizing that everyone between .30 and $1 will take their sales orders off the table by the morning. Even if it takes a little more time to complete trials.
Your fears are unfounded! and are selling based on an emotion. Not only that, some of you people are posting outrageous and biased information that lacks any DD. FWIW a majority of the failures are typically companies that have seen their market share dwindle over the years and are trying to preserve their trading status on one of the major exchanges. CYCR is not at risk from being delisted from a major exchange or has ever lost any significant revenue to speak of, therefore does not fit into this category and I believe the situation is quite the opposite. Just because trials aren't going according to your schedule you'd rather believe they had no product at all!
Growth Opportunities in Anatomic Pathology
http://www.executivehm.com/pastissue/article.asp?art=270592&issue=210
State expands women's cancer screening
http://www.chicagotribune.com/features/lifestyle/health/chi-screening28sep28,1,2726454.story
Quant: for what it's worth you should wait for a break of resistance on significant volume. Don't know about the others but I would say a break and a close above the 200SMA on volume would be bullish. With good timing, 50k shrs and some luck you could try to precipitate a break out since, unlike PRVB, I believe the short interest is much higher.
I guess not!
I sense some money is sitting on the sidelines waiting for Fed's decision this afternoon. Anyone here think even a .25bps cut would see some of that money come into CYCR?